Weintraub WS, Jones EL, Craver JM, et al.Frequency of repeat coronary bypass or coronary angioplasty after coronary artery bypass surgery using saphenous venous grafts.Am J Cardiol. 1994,73 (2) :103–112.
Motwani JG1, Topol EJ.Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention.Circulation1998, 97(9) :916–931.
Kulik A, Le May MR, Voisine P, et al.Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease(cascade) trial.Circulation,2010, 122 (25):2680–2687.
Desai ND, Cohen EA, Naylor CD, et al.A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts.N Engl J Med，2004,351 (22) :2302–2309.
Alexander JH, Hafley G, Harrington RA,et al.Efficacy and safety of edifoligide, an e2f transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: prevent iv: a randomized controlled trial.JAMA,2005, 294 (19):2446–2454.
Chesebro JH, Clements IP, Fuster V, et al.A platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency.N Engl J Med,1982,307 (2):73–78.
Chesebro JH, Fuster V, Elveback LR, et al. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations.N Engl J Med,1984,310(4):209-214.
Fremes SE, Levinton C, Naylor CD,ea al.Optimal antithrombotic therapy following aortocoronary bypass: a meta-analysis.Eur J Cardiothorac Surg,1993,7 (4):169–180.
Lim E, Ali Z, Ali A, et al.Indirect comparison meta-analysis of aspirin therapy after coronary surgery. BMJ,2003,327 (7427):1309.
Helgason CM, Bolin KM, Hoff JA, et al.Development of aspirin resistance in persons with previous ischemic stroke.Stroke ,1994,25 (12)2331–2336.
Gum PA, Kottke-Marchant K, Welsh PA,et al.A prospective,blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.J Am Coll Cardiol,2003,41 (6):961–965.
Bhatt DL, Topol EJ..Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease.Med Clin North Am,2000,84 (1):163–179 (ix).
Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med,2001,345(7):494-502.
Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med,2005,352(12):1179-1189.
 Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med,2007,357(20):2001-2015.
Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med,2009,361(11):1045-1057.
Amsterdam EA, Wenger NK, Brindis RG,et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol,2014, 64(24):e139-228 .
Windecker S, Kolh P, Alfonso F,et al. 2014 ESC/ EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J,2014,35(37):2541-2619.
Levine GN, Bates ER, Blankenship JC，et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol,2011,58(24):e44–122.
Angiolillo DJ1, Fernandez-Ortiz A, Bernardo E,et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol,2007,49(14):1505–1516.
Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J,2006,27(9):1038-1047.
Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol,2011,57(6):672-684.
Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSet of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation,2009,120(25):2577-2585.
Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a revers- ible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syn- dromes. J Am Coll Cardiol,2007,50(19):1852-1856.
Storey RF, Angiolillo D, Patil S, et al. Inhibitory effects of ticagrelor compared to clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET Substudy. J Am Coll Cardiol,2010,56(18):1456-1462.
Bonaca M P, Bhatt D L, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction.N Engl J Med,2015,372(19):1791-1800.
Li P, Gu Y, Yang Y, et al.Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial.Sci Rep,2016,24(6):31838.
Sianos G,Morel MA,Kappetein AP,et al. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention,2005,1(2):219-227.
Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol,2011,57(6):672–684.
Mannacio VA, Di Tommaso L, Antignan A, et al. Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery by-pass surgery: results from the CRYSSA(prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study. Heart,2012,98(23): 1710-1715.
Zhao Q, Zhu Y, Xu Z, et al. Effect of ticagrelor plus aspirin, ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary artery bypass grafting: a randomized clinical trial. JAMA,2018,319(16):1677-1686.
Gao G, Zheng Z, Pi Y, et al. Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, .randomized, controlled trial. J Am Coll Cardiol ,2010,56(20):1639–1643.
Sun JC, Teoh KH, Lamy A, et al. Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the preoperative aspirin and postoperative antiplatelets in coronary artery bypass grafting study. Am Heart J,2010,160(6):1178-1184.
Smith PK, Goodnough LT, Levy JH, et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol,2012,60(5):388-396.
Rafiq S, Johansson PI, Kofoed KF, et al. Thrombelastographic hypercoagulability and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): a randomized controlled trial. Platelets,2017,28(8):786-793.
Arazi HC, Doiny DG, Torcivia RS, et al. Impaired anti-platelet effect of aspirin, inflammation and platelet turnover in cardiac surgery. Interact Cardiovasc Thorac Surg,2010,10(6):863-867.
Zimmermann N, Gams E, Hohlfeld T. Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent. Eur J Cardiothorac Surg,2008,34(1):93-108.
Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy,2014,34(10):1077–1090.
Teng R. Ticagrelor: pharmacokinetic, pharmacodynamic and pharmacogenetic profile: an update. Clin Pharmacokinet,2015,54(11):1125–1138.
Neumann FJ, Sousa-Uva M, Ahlsson A,et al.2018 ESC/EACTS Guidelines on myocardial revascularization.Eur Heart J,2019,40(2):87-165.
Sousa-Uva M, Storey R, Huber K, et al. Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. Eur Heart J,2014,35(23):1510–1514.
Li P, Yang Y, Chen T,et al. Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. Sci Rep,2015,5:13789.
Teng R, Butler K.Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers. Int J Clin Pharmacol Ther,2014,52(6): 478-491.
Li H, Butler K, Yang L,et al. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. Clin Drug Investig,2012,32(2):87-97.
Teng R,Oliver S,Hayes MA,et al.Absorption,distribution,metabolism,and excretion of ticagrelor in healthy subjects.Drug Metab Dispos,2010,38(9):1514-1521.
Storey RF, Angiolillo DJ, Bonaca MP, et al.Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial.J Am Coll Cardiol,2016,67(10):1145-1154.
Guo LZ, Kim MH, Jin CD,et al. Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects. Platelets,2015, 26(5),563-569.
Hiasa Y, Teng R, Emanuelsson H. Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. Cardiovasc Interv Ther,2014,29(4):324-333.
[49Cattaneo M, Schulz R, Nylander S.Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol,2014,63(23):2503–2509.
Small DS1, Payne CD, Kothare P,et al. Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. Clin Ther,2010,32(2),365-379.
Storey RF, Becker RC, Harrington RA,et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J,2011,32(23):2945–2953.
Cannon CP, Husted S, Harrington RA,et al.Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol,2007,50(19):1844-1851.
Storey RF, Angiolillo DJ, Bonaca MP,et al. Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. J Am Coll Cardiol,2016,67(10):1145-1154.
Storey RF,Becker RC,Harrington RA,et al.Characterization of dyspnea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.Eur Heart J, 2011, 32 (23) :2945-2953.
Bergmeijer TO, Janssen PWA, van Oevelen M, et al. Incidence and Causes for Early Ticagrelor Discontinuation: A "Real-World" Dutch Registry Experience.Cardiology,2017,138(3):164-168.